Literature DB >> 20068075

Individualizing dosing of irinotecan.

Mark J Ratain1, Federico Innocenti.   

Abstract

Individualized drug dosing is a longstanding goal of clinical pharmacologists. Given the narrow therapeutic index of most anticancer agents, it is plausible that this approach would be of particular value in oncology. Irinotecan is an interesting agent for individualized dosing, given its complex metabolism and increasing knowledge of its pharmacokinetics predictors.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20068075     DOI： 10.1158/1078-0432.CCR-09-2936

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  8 in total

1.  Sequential designs for individualized dosing in phase I cancer clinical trials.

Authors:  Xuezhou Mao; Ying Kuen Cheung
Journal:  Contemp Clin Trials       Date:  2016-08-31       Impact factor: 2.226

Review 2.  Irinotecan pharmacogenomics.

Authors:  Sharon Marsh; Janelle M Hoskins
Journal:  Pharmacogenomics       Date:  2010-07       Impact factor: 2.533

3.  Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients.

Authors:  Chalirmporn Atasilp; Pichai Chansriwong; Ekapob Sirachainan; Thanyanan Reungwetwattana; Apichaya Puangpetch; Santirhat Prommas; Suwannee Sirilerttrakul; Budsaba Rerkarmnuaychoke; Sansanee Wongwaisayawan; Chonlaphat Sukasem
Journal:  J Clin Lab Anal       Date:  2017-04-10       Impact factor: 2.352

4.  All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide.

Authors:  Spinel Karas; Federico Innocenti
Journal:  JCO Oncol Pract       Date:  2021-12-03

Review 5.  Understanding patient and provider perceptions and expectations of genomic medicine.

Authors:  Michael J Hall; Andrea D Forman; Susan V Montgomery; Kim L Rainey; Mary B Daly
Journal:  J Surg Oncol       Date:  2014-07-03       Impact factor: 3.454

6.  Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene.

Authors:  Koichi Hirose; Chihiro Kozu; Koshiro Yamashita; Eiji Maruo; Mizuho Kitamura; Junichi Hasegawa; Kei Omoda; Teruo Murakami; Yorinobu Maeda
Journal:  Oncol Lett       Date:  2011-12-22       Impact factor: 2.967

7.  Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.

Authors:  Kouichi Hirose; Koushiro Yamashita; Hirofumi Takada; Noriko Kaneda; Kohei Fukami; Eiji Maruo; Mizuho Kitamura; Junichi Hasegawa; Yorinobu Maeda
Journal:  Int J Clin Oncol       Date:  2013-04-19       Impact factor: 3.402

8.  Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: Critical role of gut Ugt.

Authors:  Rongjin Sun; Lijun Zhu; Li Li; Wenjie Song; Xia Gong; Xiaoxiao Qi; Ying Wang; Romi Ghose; Song Gao; Ming Hu; Zhongqiu Liu
Journal:  Toxicol Appl Pharmacol       Date:  2020-05-05       Impact factor: 4.460
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.